Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

Conditions: Urothelial Carcinoma Interventions: Drug: Enfortumab vedotin; Drug: Pembrolizumab Sponsors: University of Michigan Rogel Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials